1. Home
  2. GILD

as 12-11-2024 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Founded: 1987 Country:
United States
United States
Employees: N/A City: FOSTER CITY
Market Cap: 114.1B IPO Year: 1992
Target Price: $96.71 AVG Volume (30 days): 7.0M
Analyst Decision: Buy Number of Analysts: 26
Dividend Yield:
3.33%
Dividend Payout Frequency: Quarterly
EPS: 0.10 EPS Growth: -97.92
52 Week Low/High: $62.07 - $98.90 Next Earning Date: 02-04-2025
Revenue: $28,299,000,000 Revenue Growth: 3.31%
Revenue Growth (this year): 6.54% Revenue Growth (next year): -0.13%

GILD Daily Stock ML Predictions

Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Dickinson Andrew D GILD Chief Financial Officer Nov 29 '24 Sell $92.76 248,645 $23,065,270.54 266,849
Parsey Merdad GILD Chief Medical Officer Nov 27 '24 Sell $91.88 164,211 $15,094,013.40 80,801
Parsey Merdad GILD Chief Medical Officer Nov 6 '24 Sell $91.50 25,590 $2,341,485.00 80,801
Mercier Johanna GILD Chief Commercial Officer Nov 6 '24 Sell $91.28 5,000 $456,400.00 73,127
Parsey Merdad GILD Chief Medical Officer Oct 1 '24 Sell $83.83 2,000 $167,660.00 80,801

Share on Social Networks: